Background: Neonatal diabetes mellitus (NDM) is a rare disorder worldwide where diabetes is diagnosed in the first 6 months of life. However, Oman has a relatively high incidence of NDM. Methods: In this study, we investigated the genetic etiologies underlying NDM and their prevalence in Oman. We collected a cohort of 24 NDM patients, with and without genetic diagnosis, referred to our center from 2007 to 2015. All patients without a genetic diagnosis were tested for mutations in 23 NDM-associated genes using a customtargeted next-generation sequencing (NGS) panel and methylation analysis of the 6q24 locus. Results: A genetic abnormality was detected in 15/24 (62.5%) of our Omani NDM patients. We report the detection of 6q24 methylation abnormalities and KCNJ11 mutations for the first time in Omani NDM patients. Unlike Western populations where NDM is predominantly due to mutations in the KCNJ11, ABCC8 and INS genes, NDM due to homozygous GCK gene mutations were most prevalent
Introduction
Oman has a relatively high incidence of neonatal diabetes mellitus (NDM). In 1995, the mean incidence was 2.2 per 100,000 live births/year and the prevalence among <5 year olds during 1995 was 2.0/100,000 [1] . NDM usually presents as hyperglycemia, failure to thrive and, in some cases, dehydration and ketoacidosis that can lead to coma in affected children within the first months of life. NDM can be classified into two types; namely, transient (TNDM) and permanent (PNDM) neonatal diabetes. Both TNDM and PNDM are rare conditions which are estimated to occur in 1:90,000-1:260,000 [2, 3] live births worldwide.
Patients with TNDM generally develop diabetes in the first weeks of life. The diabetes usually remits within the first year. Relapse to a permanent diabetic state most often occurs in adolescence or in young adulthood, likely precipitated by the physical stresses and increased insulin requirement of puberty or pregnancy. These individuals are typically younger at presentation than PNDM patients and have lower initial insulin requirements [4] . TNDM patients are also more likely to have intrauterine growth retardation than PNDM patients, but display decreased tendency for ketoacidosis. One of the common causes of TNDM is the aberrant methylation pattern at the 6q24 locus. As relapse into diabetes with progress in age or due to pregnancy is common in TNDM patients, long-term monitoring is imperative for such patients.
In PNDM, insulin secretory failure generally occurs in the late fetal or early post-natal period and does not enter remission [5] . Despite the differences between TNDM and PNDM patients, considerable overlap occurs between the two groups, so that TNDM is sometimes indistinguishable from PNDM based on clinical features at presentation.
Conclusive distinction between PNDM and TNDM is made possible by genetic testing. To date, 23 genetic causes accounting for 82% of patients with neonatal diabetes have been identified [6] . It was reported that 37% of all NDM cases were caused by mutations in the KCNJ11 and ABCC8 genes, encoding the Kir6.2 and SUR1 proteins, which are both subunits of the pancreatic K ATP channel involved in the regulation of insulin secretion [6] . Mutations in the INS gene, which provides instructions for making insulin, have been identified in about 20% of individuals with PNDM [6] . Another gene commonly implicated in PNDM is EIF2AK3 which causes Wolcott-Rallison syndrome [6, 7] . Homozygous mutations in the GCK gene are also reported as one of the rarer causes of PNDM [8] . Uncovering the molecular etiology of NDM has potentially important therapeutic consequences, as patients with KCNJ11 and ABCC8 gene mutations can transfer from insulin therapy to sulfonylureas [9] .
Given that the rate of consanguineous marriages is very high (52%) in Oman [10] , genetic testing for monogenic diabetes also has significant implications for the provision of pre-marital and pre-natal counseling of family members of NDM patients. In this study, we present new mutation results and data compiled from previously reported genetic studies on Omani NDM patients to understand the prevalence of NDM-associated mutations in Oman. It is hoped that the results of this study will provide the basis for a future strategy to introduce genetic testing for NDM disorders within the national healthcare system in Oman.
Materials and methods

Patients
For this study, we collected a cohort of 24 patients from 2007 to 2015 with a diagnosis of NDM, referred to our National Diabetes and Endocrine Center (NDEC), where nearly all Omani NDM patients requiring specialist care are referred. This study was approved by the Research and Ethics Committee of the Royal Hospital, Oman and informed consent of the parents of the patients was obtained. None of the patients had dysmorphic features or pancreatic aplasia. Twenty patients were negative for anti-glutamic acid decarboxylase (GAD) and anti-islet cell antibodies. Two of the four patients who were positive for other auto-antibodies manifested later with clinical signs such as immunodeficiency and autoimmunity [11] .
Of the 24 patients, 21 presented with hyperglycemia in the first week of life and three patients presented with skeletal abnormalities and proximal tubulopathies. One patient (Patient 15) was diagnosed at the age of 6 months with hyperglycemia and proceeded to develop thrombocytopenia (Evans syndrome) which was later treated with rituximab. Another patient (Patient 14) who presented at birth with autoimmune diabetes and autoimmune hypothyroidism, went on to develop autoimmune hemolytic anemia and hepatitis at the age of 5 months. This was then followed by alveolitis and pulmonary hemorrhage at the age of 9 months.
Patients 3 and 4 are first cousins ( Figure 1 ) and are offspring of double consanguineous unions, where even their grandparents were first cousins. Patients 5-7 belong to families distantly related to Patients 3 and 4. Patients 8 and 9 as well as Patients 11 and 12 are siblings from two different families.
Methods
Previous publications reporting mutations in six patients amongst the 24 patients in our NDM cohort were reviewed [11] [12] [13] . All the available patient clinical details were collected from our hospital records. Of the remaining 18 patients included in this study, one patient (Patient 15) was tested using whole-exome sequencing (WES) in a separate, parallel study (unpublished) .
The other 17 patients were sent to the Exeter laboratory, where the proband was first tested for the ABCC8, KCNJ11, INS and EIF2AK3 gene mutations using Sanger sequencing. This was then followed up by a targeted next-generation sequencing (NGS) of the 22 known genes implicated in NDM and where appropriate, analyzing for TNDM due to abnormalities of the 6q24 locus by methylation analysis. Family members were tested only for the mutation detected in the probands. The DNA of all patients tested in this study was extracted using standard commercial kits.
The [14] . This assay can also detect partial or whole gene deletions and duplications. All mutations detected by NGS were confirmed using Sanger sequencing analysis of the mutated exon in the affected gene.
Methylation analysis of the 6q24 locus was carried out using methylation-specific polymerase chain reaction (PCR) [6] . To determine whether any loss of maternal methylation at the 6q24 locus was caused by paternal uniparental disomy (UPD) of chromosome 6, microsatellites were analyzed at polymorphic loci throughout chromosome 6.
The pedigree diagram shown in Figure 1 was created using the program Genial Pedigree Draw.
Results
Of the 24 patients in our NDM cohort, six patients (Patients 8, 9, 11-14) had been previously investigated and their genetic test results were curated. Patients 8 and 9 were reported to carry the p.Gly261Arg mutation in the GCK gene, which encodes for glucokinase, a key enzyme responsible for regulating insulin secretion in pancreatic β-cells [12] . Patients 11-13 were previously diagnosed as having Fanconi-Bickel syndrome due to homozygous mutations in the SLC2A2 gene [13] ; which encodes for the glucose transporter type-2 protein mediating bidirectional glucose transport. Patient 14 had presented very early at 3 days after birth with insulin-dependent diabetes mellitus (IDDM) and subsequently developed autoimmune cytopenia and pulmonary hemorrhage. As the Patient 14 exhibited CD25 (IL2RA) deficiency, Sanger sequencing of the IL2RA gene was undertaken at an external laboratory and Patient 14 was found to harbor a novel homozygous mutation in the IL2RA gene [11] .
The 18/24 patients who have yet to receive a genetic diagnosis were analyzed in this study, which resulted in the detection of genetic abnormalities in nine patients. Hence, this study and previous studies [11] [12] [13] combined, provided a genetic diagnosis for 15/24 (62.5%) patients in our NDM cohort. The clinical picture and mutation details of these 15 patients are reported in Tables 1 and 2 , respectively. Patients 1 and 2 had methylation abnormalities at the 6q24 locus and were therefore diagnosed with 6q24 TNDM. To determine the underlying cause of the loss of maternal methylation at the 6q24 locus, microsatellite analysis was carried out at polymorphic loci throughout chromosome 6 [6] . Patient 1 had complete loss of methylation at the maternal 6q24 locus, whilst Patient 2 displayed homozygosity of a single paternal allele with no maternal contribution at three different non-consecutive loci on chromosome 6. This indicated that the TNDM in Patient 2 was most likely due to partial paternal UPD of the 6q24 locus.
Targeted NGS on the remaining 16 patients identified mutations in six patients (Patients 3-7 and 10) with PNDM ( Table 2) . Patients 3-7 were homozygous for the p.Glu98Ter mutation in the GCK gene. In Patient 10, we detected a heterozygous mutation in the KCNJ11 gene for the first time in Oman.
Even after targeted NGS, nine patients were still negative for any pathogenic mutations in all known NDMassociated genes. Among these nine, Patient 15 was later classified as having autoimmune disease and recruited for WES in a separate, parallel study (unpublished). As 
Discussion
Major progress has been made in understanding the genetic etiology behind NDM syndromes which present in the first year of life with 22 genes having been identified to date [6] . The most common genetic defects accounting for the majority of NDM cases worldwide are mutations in the genes encoding the two subunits of the ATP-sensitive potassium channel (K ATP ), KCNJ11 and ABCC8, and the INS gene [5, 6] . Characterizing the associated genetic defects is crucial to improving the clinical management of NDM patients. For example, patients with activating mutations in KCNJ11 and ABCC8 can be successfully transferred from insulin therapy to sulfonylureas [9] . Thus, adoption of a personalized genetic medicine approach for the management of monogenic diabetes patients will likely provide better glucose regulation and quality of life for these individuals.
In our cohort of Omani NDM patients, 15/24 individuals were found to carry genetic variants associated with NDM. This study is the first to report the detection of NDM cases due to (epi)genetic abnormalities of the 6q24 locus in Omani patients. The TNDM Patients 1 and 2 exhibited a typical clinical picture as they presented with failure to thrive and hyperglycemia. Patient 1 had a complete loss of methylation at the maternal 6q24 locus, while Patient 2 exhibited an aberrant methylation due to paternal UPD of the 6q24 locus. Genetic imprinting defects of the 6q24 locus are associated with TNDM and usually presents as severe intrauterine growth retardation, neonatal hyperglycemia in a term infant which may resolve by the age of 18 months, dehydration and absence of ketoacidosis. Macroglossia and umbilical hernia are also often present [7] . The TNDM Patients 1 and 2 were treated with small doses of intermediate insulin (NPH) at a rate of 0.3 IU/kg/ day. Neither of these patients developed diabetic ketoacidosis. Both Patients 1 and 2 are at present clinically well and have been in remission since the age of 1 year and 4 months, respectively.
We also observed two different homozygous GCK gene mutations in Oman. Patients 3 and 4 are first cousins (Figure 1 ), while Patients 5-7 belong to families distantly related to Patients 3 and 4, all within the same tribe and they carried the p.Glu98Ter in exon 3 of the GCK gene. Patients 5-7 were referred to our clinic separately, without knowledge of their familial ties. Indeed, in an example of genetic disease testing leading to relationship discovery, the family ties of Patients 5-7 with Patients 3 and 4 were discovered, even by the parents of the patients, during genetic counseling sessions held after the genetic test results were reported. However, the parents of patients 5-7 declined to provide more information necessary to create elaborate pedigrees. In Patients 8 and 9, the p.Gly261Arg mutation in the GCK gene was previously reported [12] . As homozygous mutations in the GCK gene are generally very rare worldwide [7, 8] , it is evident that the high rate of consanguinity in Oman has contributed to the persistence of gene encoding glucokinase (GCK)-associated NDM in this population. This phenomenon is reflected in the highly consanguineous pedigree shown in Figure 1 .
The GCK gene encodes glucokinase, a key regulatory enzyme in the pancreatic β-cell. Glucokinase plays a crucial role in the regulation of insulin secretion and has been termed the glucose sensor in pancreatic β-cells [15] . Given its central role in the regulation of insulin release, it is understandable that homozygous and heterozygous mutations in the GCK can cause both hyper-and hypoglycemia, respectively [16] . This study is the first report of KCNJ11 mutations in an Omani NDM patient with an Asian sub-continental Balushi ethnicity. Patient 10 in this study carries a previously known [17] heterozygous p.V59M mutation in the KCNJ11 gene. KCNJ11 encodes Kir6.2, which serves as the pore-forming subunit of the ATP-sensitive K + (K ATP ) channel in multiple tissues. This channel is a hetero-octameric structure comprising four Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits [18, 19] , of which SUR1 is expressed in β-cells and neurons [18] .
Published functional studies of the p.V59M mutation in the KCNJ11 gene have indicated that the severe neurological phenotype associated with this mutation is due to the effect of the mutation on K ATP channels in neuronal tissue [17, 20] . Functional studies in mice [21] have shown this mutation also affects the potassium channels in neuronal tissue, which probably affects brain function adversely.
Patients with the p.V59M mutation were reported to develop an intermediate developmental delay, epilepsy and neonatal diabetes (DEND) syndrome, with developmental delay and PNDM, but no epilepsy [17, 20, 21] . A similar phenotype was noted in Patient 10. It is unclear whether hypoxic insult on the brain during severe diabetic ketoacidosis episodes may have also contributed to the patient's severe phenotype.
K ATP channels can be regulated by sulfonylurea and glinide drugs, which stimulate insulin secretion through binding of the SUR subunit of the K ATP channel [22] [23] [24] [25] [26] . As a result, these drugs are widely used to treat type 2 diabetes [22] and are also effective in treating PNDM and TNDM caused by mutations in the potassium channel genes [23, 24] . Accordingly, in Patient 10, we observed a significant improvement of glycemic control after introduction of sulfonylurea therapy. At diagnosis in 2014, the glycated hemoglobin (HbA 1c ) value in Patient 10 was 7.9% (63 mmol/mol). After treatment with sulfonylurea (glibenclamide) at an initial dose of 20 mg/BID (twice a day) for 3 months, the fasting HbA 1c value in Patient 10 was in the range of 4.1%-4.7% (21-28 mmol/mol). Due to hypoglycemic episodes, the sulfonylurea dose was gradually reduced to 10 mg/BID. Since 2015, the HbA 1c values have consistently been ≤5% (31 mmol/mol). Also, before treatment with sulfonylurea, Patient 10 was completely wheelchair-bound. However, after treatment, Patient 10 displayed clinical improvement in neurological features as she was able to get up from her wheelchair and walk slowly with support.
Based on the findings of this study and previous studies on our NDM patients, we analyzed the prevalence of genetically diagnosed NDM cases in our cohort. The published report on over 1000 patients with NDM by De Franco et al. [6] showed that activating mutations in KCNJ11 or ABCC8 account for 46% of NDM cases in patients born to non-consanguineous unions; with mutations in the INS gene being the next most common etiology. On comparing the spectrum of NDM-associated mutations in Oman with other countries we observed that unlike Western populations [5, 6, 27, 28] where GCK mutations are rare in NDM patients, NDM due to homozygous mutations in the GCK gene are most prevalent in Oman (Figure 2) . Worldwide, homozygous mutations in the EIF2AK3 gene are known to be the most common cause of neonatal diabetes in patients born to consanguineous parents [7] . It is therefore striking that mutations in this gene have not been identified in our cohort.
A previous study conducted in Saudi Arabia also reported that the incidence of genes commonly mutated in NDM patients were different from that seen in Western populations [29] . As consanguinity has been widely practiced in both Oman and Saudi Arabia for centuries, it is possible that the founder effect has a role to play in contributing to relatively high numbers of individuals with rare pathogenic mutations within certain tribes in both these countries.
In this study, we chose to evaluate the prevalence as opposed to the incidence of genetic etiology underlying NDM [30] . It may be argued that the sampling of multiple affected individuals from the same family or large consanguineous tribal pedigrees contributes to an overestimation of certain genetic etiology; as seen in the case of NDM due to GCK mutations in this study. However, by focusing on the prevalence or the total number of genetically-affected individuals with NDM, we obtained a better perception of the burden of genetic testing, counseling services and clinical management that NDM disorders are likely to add to Oman's healthcare services. On the other hand, studying the incidence of genetic etiology (or different genes involved in NDM), which requires the counting of individual mutation events (or sampling a single mutation per family) would have resulted in an under-representation of the healthcare burden due to NDM in Oman. This is a significant point to consider because the total number of NDM-affected individuals being born each year is a critical parameter used to assess whether the introduction of genetic testing, genetic counseling and proactive premarital and prenatal screening within the affected families of NDM patients is effective in reducing numbers of NDM patients over time. Our results also indicate the need for a genetic testing strategy that takes into account the ethnicity and tribal affiliations of the patients.
It is to be noted that only 62.5% (15/24) of our NDM patients had a genetic defect known to be associated with NDM. The genetic disorder underlying NDM in the remaining nine patients is still unknown despite being analyzed using the targeted sequencing panel and/or exome sequencing. These nine patients were all negative for autoantibodies and other physical or mental abnormalities. All nine patients will be recruited for a future study to look for novel causes of NDM.
As the NDEC is the national center for specialist diabetic care to which nearly all Omani NDM patients have been referred to since 2007, estimating and monitoring NDM prevalence among the population has significant implications not just for treatment of NDM patients, but also in adjudicating sufficient resources for genetic counseling and the provision of pre-marital and pre-natal screening in family members of NDM patients in Oman. However, given the large genetic heterogeneity underlying NDM and the possibility of yet more genes being associated with NDM in the future, a strategic approach to genetic testing for NDM disorders is essential. It is hoped that this study will influence and guide the adoption of an effective protocol for NDM genetic testing in Oman with the aim of faster genetic diagnosis for NDM patients and timely clinical intervention.
